IRIS UniCatt

Cassano, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.710
EU - Europa 4.198
AS - Asia 3.746
SA - Sud America 659
AF - Africa 117
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 14.442
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.542
SG - Singapore 1.756
DE - Germania 1.483
CN - Cina 727
SE - Svezia 636
BR - Brasile 529
IT - Italia 501
VN - Vietnam 418
PL - Polonia 326
FR - Francia 291
GB - Regno Unito 229
IN - India 177
IE - Irlanda 144
UA - Ucraina 144
BD - Bangladesh 136
FI - Finlandia 120
ID - Indonesia 104
CA - Canada 84
JP - Giappone 83
RU - Federazione Russa 78
HK - Hong Kong 77
TR - Turchia 60
AR - Argentina 52
MX - Messico 51
BE - Belgio 41
CI - Costa d'Avorio 37
IQ - Iraq 37
ZA - Sudafrica 36
NL - Olanda 34
AT - Austria 32
ES - Italia 32
IR - Iran 25
EC - Ecuador 21
PK - Pakistan 18
CZ - Repubblica Ceca 17
LT - Lituania 17
SA - Arabia Saudita 17
CO - Colombia 14
KR - Corea 14
MA - Marocco 13
UZ - Uzbekistan 12
VE - Venezuela 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
CL - Cile 11
PY - Paraguay 10
RO - Romania 10
LU - Lussemburgo 8
PH - Filippine 8
NP - Nepal 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
IL - Israele 6
OM - Oman 6
PE - Perù 6
AL - Albania 5
AU - Australia 5
BG - Bulgaria 5
CR - Costa Rica 5
JM - Giamaica 5
JO - Giordania 5
KE - Kenya 5
LV - Lettonia 5
MD - Moldavia 5
MY - Malesia 5
EG - Egitto 4
LB - Libano 4
NO - Norvegia 4
SN - Senegal 4
TN - Tunisia 4
BO - Bolivia 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
RS - Serbia 3
SV - El Salvador 3
AO - Angola 2
BB - Barbados 2
CG - Congo 2
CM - Camerun 2
DK - Danimarca 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
KW - Kuwait 2
ML - Mali 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AW - Aruba 1
Totale 14.426
Salva come PNG Salva come JPEG
Città #
Singapore 1.030
Chandler 795
Ashburn 537
San Jose 463
Warsaw 307
New York 175
Fairfield 171
Beijing 155
Dublin 142
Los Angeles 133
Ho Chi Minh City 127
Wilmington 125
San Mateo 120
Ann Arbor 116
Hanoi 104
Jacksonville 100
Houston 96
Lauterbourg 93
Nürnberg 91
Woodbridge 91
Jakarta 88
Nanjing 83
Seattle 76
Council Bluffs 75
Rome 75
Boston 74
Chicago 74
Tokyo 74
Dallas 69
Frankfurt am Main 68
Hong Kong 68
Cattolica 66
Munich 63
Helsinki 62
Milan 60
Cambridge 58
Princeton 57
The Dalles 53
Dearborn 52
São Paulo 50
Redmond 48
Hyderabad 47
Moscow 45
Hefei 42
London 42
Marseille 41
Brussels 40
Santa Clara 40
Abidjan 37
Izmir 36
Nanchang 32
Orem 32
Boardman 31
Shanghai 30
Denver 29
Redwood City 28
Toronto 27
Bremen 26
Buffalo 26
Lawrence 25
Brooklyn 24
Matera 24
Paris 24
Falls Church 23
Montreal 21
Augusta 20
Johannesburg 19
Leawood 19
Norwalk 19
Nuremberg 19
Mountain View 18
Rio de Janeiro 18
Vienna 18
Haiphong 17
Poplar 17
Amsterdam 16
Phoenix 16
Atlanta 15
Chennai 15
Düsseldorf 15
Hebei 15
Manchester 15
San Francisco 15
Hangzhou 14
Kraków 14
Lancaster 14
Lappeenranta 14
Stockholm 14
Dong Ket 13
Mumbai 13
Changsha 12
Da Nang 12
Guangzhou 12
Kent 12
Kish 12
Mexico City 12
Newark 12
San Diego 12
Tianjin 12
Turku 12
Totale 7.658
Salva come PNG Salva come JPEG
Nome #
Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival 411
Pembrolizumab as first-line treatment for metastatic uveal melanoma 352
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy 351
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real- world experience 343
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 322
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 255
Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma 236
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 236
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 233
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 227
[Gastrointestinal stromal tumors] 213
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 211
Thymoma in patients with MG: characteristics and long-term outcome 199
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo 196
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases 195
Gastrointestinal stromal tumors (GISTs) and second malignancies A novel sentinel tumor? A monoinstitutional, STROBE-compliant observational analysis 193
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 187
PDGFRA-mutant syndrome 186
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 183
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients 181
Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study) 178
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 175
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome 175
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 166
Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. 163
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 162
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 159
Are TKIs favourable for the elderly with non-small-cell lung cancer? 159
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 159
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 155
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity 151
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 151
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 150
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 149
Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study 148
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 147
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 146
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 146
Osteoradionecrosis incidence in pre‐radiation teeth extractions: A prospective study 143
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 142
Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. 142
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer 142
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 142
First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen) 140
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: A single institution phase II study 139
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 139
Advanced colon cancer: staging and prognosis by CEA test 138
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 136
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 136
[Gastrointestinal stromal tumors] 135
Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium 134
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 131
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. 129
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 129
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? 127
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy? 127
Divergent gastrointestinal stromal tumors in syndromic settings 126
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. 125
Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board 125
Successful "on- demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. 123
eComment. Iterative metastasectomy for recurrent pulmonary disease from colorectal cancer: A challenging issue 122
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 120
Novel epigenetic eight-gene signature predictive of poor prognosis and msi-like phenotype in human metastatic colorectal carcinomas 120
In reply to the letter to the editor regarding "Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board" 120
Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity. 119
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 117
Operator learning curve for transradial liver cancer embolization: Implications for the initiation of a transradial access program 116
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 113
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 109
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer 108
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study 105
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 105
Authors' reply “Osteoradionecrosis incidence in preradiation teeth extractions: A prospective study” 104
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 104
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 104
Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? 103
Oral Health Status in Patients with Head and Neck Cancer before Radiotherapy: Baseline Description of an Observational Prospective Study 103
Long term follow up of a pilot study with neoadjuvant EEP ( epidoxorubicin, Etoposide and Cisplatin) in gastric cancer. 102
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 102
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors 101
Primary cardiac synovial sarcoma: A review correlating outcomes with surgery and adjuvant therapy 100
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 98
Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms 97
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer 97
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 96
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 91
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 91
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 89
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 85
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study 85
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. 82
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) 76
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 76
Targeted therapy in advanced gastric carcinoma: The future is beginning 74
Triple positive breast cancer: A distinct subtype? 72
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 65
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 50
Totale 14.627
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022973 79 45 21 111 60 40 22 149 52 59 132 203
2022/20232.031 272 285 158 348 110 240 98 192 197 38 66 27
2023/2024794 32 223 31 32 30 121 54 39 13 32 86 101
2024/20251.802 37 65 139 98 152 66 48 100 237 223 330 307
2025/20265.314 685 132 275 685 989 290 965 244 373 286 178 212
2026/2027126 126 0 0 0 0 0 0 0 0 0 0 0
Totale 14.627